Breast Cancer (Molecular Diagnostics and Gene Therapy Attempts)
Article Sidebar
-
Molecular Testing, Breast Cancer Diagnosis, Breast Cancer Genetics, Breast Cancer, Breast Cancer Treatment
Abstract
Breast cancer is one of the most common cancers and the foremost cause of death for women around the world. It may begin as a normal disease, then it may spread deep to part of the body, especially to the lymph node, bones, and spine, making it more deadly. The chances of breast cancer increase with increasing age, drinking alcohol, and taking oral contraceptives. Breast cancer represents 23% of all new cancers and 14% of all cancer deaths. This established fact makes it the most deadly tumor in women. According to recent studies, predisposition factors are grouped according to associating them with the occurrence of the disease; for example, the mutation in BRCA1 leads to the risk of infection increasing by 80%, and the BRCA2 mutation increases the risk by 45%. Breast cancer associated with these mutations occurs in younger women. The diagnosis of breast cancer begins with a physical examination and diagnosing it through a mammogram or ultrasound. There are many analyses that work on analyzing and identifying the BRCA1/2 mutation using different molecular tools, including (MS-PCR, DNA sequencing, and next-generation DNA sequencing). This method has shown its effectiveness in separating single nucleotides, and its advantages are its high accuracy and speed of analysis, as identifying mutations and early detection help to provide many treatments, especially that breast cancer is curable if it is diagnosed accurately in the early stage. There are many methods used in its treatment, including chemotherapy and hormone therapy, radiation therapy, gene therapy, etc., that improve expectations and survival.
Full text article
References
[1]-Harris J, Lippman M, Veronesi U, et al. Breast Cancer (3 parts). N Engl J Med. 1992:327:319–479.
[2]-Costanza ME. Epidemiology and risk factors for breast cancer. In: UpToDate. 2001:9:2–3.
[3]-Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
[4]-Antoniou, A., P.D. Pharoah, H.A. Risch, J.E. Eyfjord and J.L. Hopper et al., 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet., 72: 1117-1130. DOI: 10.1086/375033
[5]-Butcher, D.T., D.N. Mancini-DiNardo, T.K. Archer and D.I. Rodenhiser, 2004. D.N.A. binding, sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter, Int. J. Cancer, 111: 669-678. DOI: 10.1002/ijc.20324.
[6]-Wijdan, A., 2009. Screening of breast mass in iraqifemales: al-kindy hospital breast clinic. Am. J. Inf Dis., 5: 320-323. DOI: 10.3844/ajidsp.2009.320.323.
[7]-Pickl, M. and C.H. Ries, 2009. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab trastuzumabActivation of HER2 in 3D. Oncogene, 28: 461-468. DOI: 10.1038/onc.2008.394.38
[8]-Diermeier-Daucher, S., M. Hasmann and G. Brockhoff, 2008. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann. N Y. Acad Sci., 1130: 280-286. DOI: 10.1196/annals.1430.003
[9]-Hollmen, M., J.A. Maatta, L. Bald, M.X. Sliwkowski and K. Elenius, 2009. Suppression of breast cancer cell growth by a monoclonal antibodytargeting cleavable ErbB4 isoforms. Oncogene, 28: 1309-1319. PMID: 19151766
[10]-Tovey, S.M., B. Dunne, C.J. Witton, T.G. Cooke and J.M. Bartlett, 2006. HER4 in breast cancer: comparison of antibodies against intra-and extracellular domains of HER4. Breast Cancer Res., 8: 1-8. DOI: 10.1186/bcr1394
[11]-Mufti, M.M.R., M.P. Mostari, G.K. Deb, K. Nahar and K.S. Huque, 2009. Genetic diversity of red chittagong cattle using randomly amplified polymorphic DNA markers. Am. J. Animal Vet. Sci., 4: 1-5. DOI: 10.3844/ajavsp.2009.1.5.37
[12]-Jones, F.E., 2008. HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer. J. Mammary Gland Biol. Neoplasia, 13: 247-258. DOI: 10.1007/s10911-008-9076-6.
[13]-Naresh, A., W. Long, G.A. Vidal, W.C. Wimley and L. Marrero et al., 2006. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res., 66: 6412-6420. DOI: 10.1158/0008-5472.CAN-05-2368.
[14]-DGHS & MOH & FW (2012) Health Bulletin, Dhaka: DGHS, MOH&FW.
[15]-Kumar GL, BadveSS (2008) Milestone in the discovery of HER2 Proto-Oncogene and Trastuzumab (HerceptinTM)Connection 9.14.
[16]-Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
[17]-Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, et al. (2001). Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. Journal of the National Cancer Institute 93(21): 1624-1632.
[18]-Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B. and King, M.C.:Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990.
[19]-Wooster, R., Bignell, G., Lancaster, J. et al.:Identification of the breast cancer susceptibility gene BRCA2. Nature 1995.43
[20]-Miki, Y., Swensen, J., Shattuck-Eidens, D.,Futreal, P.A., Harshman, K., Tavtigian, S., Liu,Q., Cochran, C., Bennett, L.M., Ding, W. et al.:A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994.
[21]-Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., and Kern, S. E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res., 56: 5360–5364, 1996.
[22]-Thorlacius, S., Olafsdottir, G., Tryggvadottir, L., Neuhausen, S., Jonasson, J. G., Tavtigian, S. V., Tulinius, H., Ogmundsdottir, H. M., and Eyfjord, J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet., 13: 117–119, 1996.
[23]-Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88: 265–275, 1997.
[24]-Wong, A. K. C., Pero, R., Ormonde, P. A., Tavtigian, S. V., and Bartel, P. L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem., 272: 31941–31944, 1997.
[25]-Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95-121.
[26]-Easton, D. F. (1999). How many more breast cancer predisposition genes are there Breast Cancer Res. 1, 14-17
[27]-Nathanson, K. N., Wooster, R. and Weber, B. L. (2001). Breast cancer genetics: what we know and what we need. Nat. Med. 7, 552-556.
[28]-Zanetti R, Tazi MA, Rosso S. New data tells us more about cancer incidence in NorthAfrica. Eur J Cancer 2010; 46(3): 462-6
[29]-Al sarbot Amal ,Marwan Mahomed ,Ereebe nor eldeen (2011) Mutations of BRCA1 Gene and Its Detection Among Libyan Women with Breast Cancer.Abstracts of postgraduate studies (Master-PhD)University of Tripoli .
[30]-Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012.CA Cancer J Clin 62: 10-29.
[31]-Thomson AK, Heyworth JS, Girschik J, Slevin T, Saunders C, et al. (2014) Beliefs and perceptions about the causes of breast cancer: a case-control study. BMC Res Notes 7: 558.
[32]-Wei L. (2007). Genetic Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer of Hong Kong Chinese. Abstract of thesis for the degree of Doctor of Philosophy at the University of Hong Kong.
[33]-Acharya UR, Ng UE, Chang YH, Yang J, and Kaw GJ. Computer-based identification of breast cancer using digitized mammograms. J Med Syst. 2008;32(6):499-507.
[34]-Baltzer PA, Freiberg C, Beger S, Vag T, Dietzel M, Herzog AB, Gajda M, Camara O, and Kaiser WA. Clinical MR-mammography: are computer-assisted methods superior to visual or manual measurements for curve type analysis?a systematic approach. Acad Radiol. 2009;16(9):1070-6.
[35]-Baeten SA, Baltussen RM, Uyl-de Groot CA, Bridges J, and Niessen LW. Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control. Value Health. 2010;13(5):573-9.
[36]-PHIPPS, A. & LI, C. 2010. Breast Cancer Biology and Clinical Characteristics.In: LI, C. (ed.) Breast Cancer Epidemiology. Springer New York.
[37]-COMPTON, C., BYRD, D., GARCIA-AGUILAR, J., KURTZMAN, S.,OLAWAIYE, A. & WASHINGTON, M. 2012. Breast. In: COMPTON, C. C., BYRD, D. R., GARCIA-AGUILAR, J., KURTZMAN, S. H., OLAWAIYE, A. & WASHINGTON, M. K. (eds.) AJCC Cancer Staging Atlas. Springer New York.
[38]-FABBRI, A., CARCANGIU, M. & CARBONE, A. 2008. Histological Classification of Breast Cancer. In: BOMBARDIERI, E., GIANNI, L. & BONADONNA, G. (eds.) Breast Cancer. Springer Berlin Heidelberg.
[39]-American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.
[40]-Singh H, Nugent Z, Decker K, Demers A, Samadder J, Torabi M, et al.Geographic variation and factors associated with colorectal cancer incidence in Manitoba. Can J Public Health 2018;108:e558-64.
[41]-Sabour R, Fard ZT. The relationship of age and serum prostate-specific antigen with FAS 1377 G/A in prostate cancer. Libyan J Med Sci 2018;2:8-11.
[42]-Akhtar SS, Abu Bakr MA, Dawi SA, Huq IU. Cancer in Libya –A retrospective study (1981-1985). Afr J Med Med Sci 1993;22:17-24.
[43]-WHO-Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://www.globocan. iarc.fr/Default.aspx.
[Last accessed on 2018 Feb 20].
[44]-Elzouki AN, Alkomsi S. Pattern of gastrointestinal tract cancer in the Eastern part of Libya. Garyounis Med J 2005;22:27-31.
[45]-El-Mistiri M, El-Mangush M, El-Sahli N, El-Hamri F, Habil S, Bugrara F, et al. Cancer incidence in Eastern Libya: Preliminary result of the year 2003. Tunis Med 2005;83 Suppl 12:18-9.
[46]-El Mistiri M, Pirani M, El Sahli N, El Mangoush M, Attia A, Shembesh R, et al. Cancer profile in Eastern Libya: Incidence and mortality in the year 2004. Ann Oncol 2010;21:1924-6.
[47]-Elzouki AN, Buhjab SI, Alkialani A, Habel S, Sasco AJ. Gastric cancer and Helicobacter pylori infection in the Eastern Libya: A descriptive epidemiological study.Arab J Gastroenterol 2012;13:85-8.
[48]-El Mistiri M, Verdecchia A, Rashid I, El Sahli N, El Mangush M, Federico M, et al. Cancer incidence in Eastern Libya: The first report from the Benghazi cancer registry, 2003. Int J Cancer 2007;120:392-7.
[49]-Martin LJ, Melnichouk O, Guo H, Chiarelli AM, Hislop TG, Yaffe MJ, et al., 2010. Family history, mammographic density, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev; 19(2):456-63.
[50]-Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S, 2013. Relationship Between Family History of Breast Cancer and Clinicopathological Features in Moroccan Patients. Ethiopian Journal of Health Sciences; 23(2):150-157.
[51]-Chouchane, L., Boussen, H. & Sastry, K. S. R. 2013. Breast cancer in arab populations: Molecular characteristics and disease management implications. The Lancet Oncology, 14, e417-e424.
[52]-EL-HARITH, E. H. A., ABDEL-HADI, M. S., STEINMANN, D. & DORK, T. 2002. BRCA1 and BRCA2 mutationsin breast cancer patients from Saudi Arabia. Saudi Medical Journal, 23, 700-704.
[53]-Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, et al., 2004. Clinical breast examination: practical recommendations for optimizing performance and reporting. CA: a cancer journal for clinicians 54 (6): 327-344.
[54]-El Mistiri M, Pirani M, El Sahli N, El Mangoush M, Attia A, Shembesh R, et al. Cancer profile in Eastern Libya: Incidence and mortality in the year 2004. Ann Oncol 2010;21:1924-6.
[55]-Anderson I, Aspergren K, Janson L, et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ 1988; 297: 943-948.
[56]-Sydney: NHMRC National Breast Cancer Centre, 1999
[57]-Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94: 1445-1457.
[58]-Semiglazov VF, Sagaidak VN, Moiseyenko VM, Mikhailov EA. Study of the role of breast cancer self-examination in the reduction of mortality from breast cancer.The Russian Federation/World Health Organization study. Eur J Cancer 1993;29A: 2039-2046.
[59]-Watson M, 2008. Assessment of suspected cancer. InnoAiT 1 (2): 94-107.
[60]-Tabar L, Gad A. Screening for breast cancer: the Swedish trial. Radiology 1981; 138: 219-222.
[61]-World Health Organization, International Agency for Research on Cancer. IARC handbooks of cancer prevention: breast cancer screening. Vol 7. Lyon: IARC Press, 2002.
[62]-Shah R, Rosso K, Nathanson SD (2014) Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 5: 283-298.
[63]-Saini KS, Taylor C, Ramirez AJ, Palmieri C, GunnarssonU, Schmoll HJ, et al., 2011. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Annals of Oncology 23 (4): 853-9
[64]-Sparano JA (2006) The TAILORx trial: individualized options fortreatment. Community oncology 3: 494-496.
[65]-Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC,et al., 2009. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. The American Journal of Surgery 198 (1): 83-91
[66]-Yashar CM, Blair S, Wallace A, Scanderbeg D, 2009. Initial clinical experience with the Strut-Adjusted Volume Implant brachytherapy applicator for accelerated partial breast irradiation. Brachytherapy 8 (4): 367-72.
[67]-Kelly K, Dean J, Comulada W, Lee S. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol. 2010;20:734–42.
[68]-Ahmed B. Awareness and practice of breast cancer and breast self examination among university students in Yemen. Asian Pac J Cancer Prev. 2010;11:101–6.
[69]-Cam O, Gvmvs A. Breast cancer screening behavior in Turkish women: relationships with health beliefs and self-esteem, body, perception and hopelessness. Asian Pac J Cancer Prev. 2009;10:49–56.
[70]-Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V. Bajamonde A, et al., 2001. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine 344 (11): 783-792.
[71]-Boughey J, Nguyen T. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph bodes. Breast Dis YB Quart. 2016;27:282–4.
[72]-Hamid O,Sznol M,Pavlick AC,Kluger HM, Kim KB, Boasberg PD,et al., 2010. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. Journal of Clinical Oncology (Meeting Abstracts) 28(15_suppl): 8525.
[73]-Rubanyi GM. The future of human gene therapy. Mol Aspects Med 22:113-42, 2001.
[74]-Zhao M, Ramaswamy B (2014) Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol 5: 248-262.
[75]-Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33-40, 2001
[76]-Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 80:35-47, 1998.
[77]-Brown MD, Sch.tzlein AG, Uchegbu IF. Gene delivery with synthetic (non-viral) carriers. Int J Pharm 229:1-21, 2001.
[78]-Pouton CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Deliv Rev 34:3-19, 1998.
[79]-Chen J, Reeves L, Cornetta K. Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors. Hum Gene Ther 12:61-70,2001
[80]-Kochanek S, Schiedner G, Volpers C. High-capacity ÔgutlessÕ adenoviral vectors. Curr Opin Mol Ther 3:454-63,2001.
[81]-Chen QR, Zhang L, Gasper W, Mixon AJ. Targeting tumor angiogenesis with gene therapy. Mol Genet Metab74:120-7, 2001
[82]-NPTEL –Bio Technology –Genetic Engineering & Applications Joint initiative of IITs and IISc –Funded by MHRD Page (1 of 69) ,MODULE 8-LECTURE 1 GENE THERAPY: INTRODUCTION AND METHODS, Joint initiative of IITs and IISc –Funded by MHRD
[83]-Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636-646. doi:10.1038/nrg2842
[84]-Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.Cancer Res.1996;56:4735–4742.
[PubMed]
[Google Scholar]
[85]-Bridgewater JA, et al. Expression of the bacterial nitroreductase enzymein mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.Eur J Cancer.1995;31A:2362–2370.
[PubMed]
[Google Scholar]
[86]-Huber BE, Richards CA, Austin EA. VDEPT: an enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer.Advanced Drug Delivery Reviews.1995;17:279–292.
[Google Scholar]
[87]-Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytidine to fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.Proc Natl Acad Sci USA.1994;91:8302–8306.
[PMC free article]
[PubMed]
[Google Scholar]
[88]-https://www.ncbi.nlm.nih.gov/pmc/articles/PMC315452/figure/F1/
[89]-Bertram JS. The molecular biology of cancer. Mol Aspects Med 21:167-223, 2001.
[90]-Cheng EH, Pirollo KF, Bouker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today 6:358-65, 2000.
[91]-. Wang TJ, Huang MS, Hong CY Tse V, Silverberg GD, Hsiao M. Comparison of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem Biophys Res Commun 287:173-80, 2001.
[92]-Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1, and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18:1663-76, 1999.
[93]-Chen QR, Zhang L, Gasper W, Mixon AJ. Targeting tumor angiogenesis with gene therapy. Mol Genet Metab 74:120-7, 2001.
[94]-NanniP, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls. Ann Oncol 10:261-6, 1999.
[95]-Goldsyby RA, Kindt TJ, Osborne BA. Cancer and the immune system. Kuby Immunology 4th edition. W.H. Freeman and Company. New York. 2000, pp:539-61
[96]-Norman KL, Farassati F, Lee PWK. Oncolytic viruses and cancer therapy. Cytokine & Growth Factor Rev 12:271-82, 2001.
[97]-King RJB. Oncogenes, repressor genes and viruses. Cancer biology 2nd edition. Pearson Educational Limited. England, 2000, pp: 71-95.
[98]-Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol72:9470-8, 1998.
[99]-Lewin AS, Hauswirth WW. Ribozyme gene therapy: applications for molecular medicine. Trends Mol Med 7:221-8, 2001.
[100]-David AD. Peptide nucleic acids: versatile tools for gene therapy strategies. Adv Drug Deliv Rev 44:81-95, 2000.
[101]-Futreal,P.A.,Q.Liu,D.Shattuck-Eidens, C. Cochran, K. Harshman,S. Tavtigian, L.M .Bennett, A. Haugen-Strano, J.Swensen, &Y., Miki, et al., BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122(1994)
[102]-Szabo,C.I. & M.C. King: Inherited breast and ovarian cancer. Hum. Mol. Genet. 4 Spec No, 1811-1817(1995)
[103]-LAloo,F.(2002).Genetics for Oncologists .RemedicaPubilishing Ltd.
[104]-Rodenhiser,D.I., J.D.Andrews,D.N.Mancini,J.H.Jung,& S.M., Singh: Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumoursuppressorgene. Mutat. Res. 373, 185-195(1997)
[105]-Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9: 321-345.
[106]-Crook, T. et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumours. Oncogene 17, 1681–1689 (1998).
[107]-Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N. & Foulkes, W. P. TP53 mutations in breast cancer associated with BRCA1 orBRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 61, 4092–4097 (2001).
[108]-Moynahan,M.E.:The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene21, 8994-9007(2002).
[109]-Arizti,P., L.Fang,I. Park,Y. Yin,E. Solomon, T.Ouchi, S.A. Aaronson & S.W. Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. Mol. Cell Biol.20, 7450-7459(2000).
[110]-van der Poel S, Jansen J, van der Rejiden B, Löwenberg B. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction of whole blood. Blood1998;91:2208-2211
[111]-Wittersheim M, Büttner R, Markiefka B (2015) Genotype/Phenotype correlations in patients with hereditary breast cancer. Breast Care(Basel) 10: 22-26.
[112]-Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36: 237-249
[113]-American Cancer Society. (2013, October 24). How is breast cancer staged.
[114]-Claus ,E.B., Risch ,N.& Thompson ,W.D.(1991).Genetic analysis of breast cancer in the cancer andsteroid hormone study. Am J Hum Genet,48,232-42.
[115]-Schubert,E.L.,Mefford ,H, C., Dann, J, L., Argonza,R.H.,Hull,j.&King,M. C. (1997).BRCA1 and BRCA2 mutation in Ashkenazi Jewsfamilies with breast and ovarian cancer . Genet Test, 1,41-6.
[116]-Reece, J,B., Urry, A.L.Cain, M.L., Wasserman, S.A., Minorsky,P.V.& Jackson ,R.B.(2011). Campbell biology book(9thEd.).Pearson Education.Inc.
[117]-Dulfoth,R.M.,Carvallo,S., Heinrich, J. K.,Shinato, J.Y., Dossantos,c.c. &Zeferino,L.C. (2005).Analysis of BRCA1 and BRCA2 mutation in Brarilian breast cancer patient with positive family history . soo paulo Med J, 123,192-197.
[118]-Pohlreich, P,Zikan, M., Stribrna, J., Kleib, Z., janatove, M .&Kotlas, J.(2005). Hihgh proportion of recurrent gremline mutations in area . breast cancer Research ,7,R728-R736.
[119]-Kadouri,L.,Hubert,A.,Rotenberg,Y.,Hamburger,T., et al.(2007).Cancer risker in carriers of the BRCA1/2 mutation in a hospital-based of unselected breast cancer cases. Chirurgia ,108,468,472.
[120]-Thompson,D.&Easton,D.F.(2002).The breast cancer linkage consortium(2002).cancer incidence in BRCA1 mutation carriers journal of the National cancer Institute,94(18),1358-1365
[121]-Sipe,H.J.Jr,Jordan,S.J. Hanna ,P.M&Mason,R.P.(1994).The metabolism of 17B-estradiol by lactoperxidase: a possible source of oxidativestress I breast cancer .Carcinogenesis, 15,2637-2643.
[122]-Hamada ,J.et al .(2001). Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation .J.Natl Cancer Inst.,93,214-219.
[123]-The breast cancer linkage consortium (1999).Cancer risk in BRCA2 mutation carriers journal of the National cancer Institute,91(15),1310-1316.
[124]-Couch,F.J.&Weber,B.L.(1996).Mutations and polymorphisms in the familial early –onset breast cancer(BRCA1)gen.Breast cancer Information Core. Hum Mutat,8,8-18.
[125]-Tonin,P.,Serova,O.,Lenoir,G.,Lynch,H.,Durocher,F.,Simard,J.,etal.(1995).BRCA1 mutations in Ashkenazi jewishwomen.Am J Hum Genet,57,189
[126]-Struewing,J.P.,Hartge,P.,Wacholder,S.,Baker,S.M.,Berlin,M.,M.,McAdams,M.,et al.(1997).The risk of cancer with specific mutation of BRCA1 an BRCA2 among
[127]-Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of earlyonset breast cancer. J Natl Cancer Inst 2001; 93(16): 1215-23.
[128]-Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT mutations inAshkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13(1):126-8.
[129]-Gal I, GershoniBaruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, et al. The1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer 2004; 3(1): 11-4.
[130]-Olufunmilayo ,I. o ., Tatyana .A. G.,Rita N &Dezheng H. (2008). Advances in breast cancer: pathways to personalized medicine. Clinical cancer Research, 14, 7988-7999
[131]-Elfandi Lamia , Ghada Said , Saleh Suleiman Saleh , Mohamed Marwan , Nabil Enattah , (2016). Analysis of 6174delT Mutation in BRCA2 Gene by Mutagenically
[132]-Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: a guide for oncologists. Crit Rev Oncol Hematol. 2015;96(3):463e474.
[133]-Fan H, Ives AR, Surget-groba Y, et al. An assembly and alignment-free method of phylogeny reconstruction from nextgeneration sequencing data. BMC Genomics. 2015;16(1):522.
[134]-D’argenio V, Frisso G, Precone V, et al. DNA sequence capture and next-generation sequencing for the molecular diagnosis of genetic cardiomyopathies. J Mol Diagn. 2014;16:32e44.
[135]-D’arenio V, Esposito MV, Telese A, et al. The molecular analysis of BRCA1 and BRCA2: next-generation sequencing supersedes conventional approaches. Clin Chim Acta. 2015; 446:221e225.
[136]-Li S, Yang C, Zhai L, et al. Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast. Breast Cancer Res Treat. 2012;136(1):77e87
[137]-Sommer SS, Groszbach AR, Bottema CD: PCR amplification of specific alleles (PASA) is a general method for rapidly detecting known single−base changes. Biotechniques 1992, 12, 82–87.
[138]-Okayama H, Curiel DT, Brantly ML, Holmes MD, Crystal RG: Rapid, nonradioactive detection of mutations in the human genome by allele−specific amplification. J Lab Clin Med 1989, 114, 105–113.
[139]-Stephen,L.(1995).Current protocol in human genetics, 9.8 .1-9.8 .12.john Wiley & Sons ,Inc.
[140]-Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-3629.
[141]-Lindholm J. Development and Validation of HPLC method for Analytical and Preparative Purpose. Acta Universities Upsaliensis Uppsala. 2004; 13-14.
[142]-Rao BV,Sowjanya GN,Ajitha A, Rao Uma MV. A review on stability indicating HPLCmethod development,World journal of pharmacy and pharmaceutical sciences.2015; 4(8):405-423
[143]-Wanguo Liu, David I. Smith, Keri J. Rechtzigel, Stephen N. Thibodeau and C. David James 121-Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations . Nucleic Acids Research, 1998, Vol. 26, No. 6
[144]-Grompe, M. (1993) Nature Genet., 5, 111–117.
[145]-Cotton, R.G.H. (1997) Trends Genet., 13, 43–66.
[146]-Oefner, P.J. and Underhill, P.A. (1995) Am. J. Hum. Genet., 57 (Suppl.),A266.
[147]-Underhill, P.A., Jin, L., Lin, A.A., Mehdi, S.Q., Jenkins, T., Vollrath, D., Davis, R.W., Cavalli-Sforza, L.L. and Oefner, P.J. (1997) Genome Res., 7, 996–1005.
[148]-Huber, C.G., Oefner, P.J. and Bonn, G.K. (1993) Anal. Biochem., 212,351.35
[149]-Hayward-Lester, A., Oefner, P.J., Sabatini, S. and Doris, P.A. (1995) Genome Res., 5, 494–499.
[150]-James, C.D., Carlbom, E., Dumanski, J., Hansen, M., Nordenskjold, M., Collins, V.P. and Cavenee, W.K. (1988) Cancer Res., 48, 5546–5551.
[151]-Charde MS, WelankiwarAS and Kumar J. Method development by liquid chromatography with validation.International Journal of Pharmaceutical Chemistry.2014; 4(2):57-61.
[152]-Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K.A, Lin, H., Lignon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H.F. andTavtigian, S.V. (1997) Nature Genet., 15, 356–362.
[153]-Wanguo Liu, David I. Smith, Keri J. Rechtzigel, Stephen N. Thibodeau and C. David James 121-Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations . Nucleic Acids Research, 1998, Vol. 26, No. 6.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the University of Sebha where authors who have published their articles in the journal of the university of Sebha should how they can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
Privacy Statement The names and e-mail addresses entered on the Sabha University Journal site will be used for the aforementioned purposes only and for which they were used.